Yükleniyor... / Loading...
This study looks at combination therapy using mycophenolate mofetil (Cellcept) together with human interferon beta 1a (Rebif) in patients with relapsing remitting multiple sclerosis. People aged 18 to 65 who had RRMS and were eligible to start interferon therapy could take part. The study was carried out in Early Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * diagnosed with relapsing remitting multiple sclerosis * eligible to initiate interferon therapy * between he ages of 18-65, inclusive Exclusion Criteria: * have received corticosteroids within 30 days prior to study start * have ever received cyclophosphamide or mitoxantrone * have received Imuran or methotrexate in the last 3 months * females that are pregnant or breastfeeding are excluded